Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin

Lupus

Volumn 6, Issue 7, 1997, Pages 590-596

  Mohri, M ^a   Sata, M ^a   Gomi, K ^a   Maruyama, Y ^b   Osame, M ^b   Maruyama, I ^b  

^a ASAHI CHEMICAL INDUSTRY CO   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Behcet's disease; Protein C; Protein S; Systemic lupus erythematosus; Thrombomodulin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; LUPUS ANTICOAGULANT; PROTEIN C; THROMBOMODULIN;

ARTICLE; BEHCET DISEASE; BLOOD CLOTTING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

EID: 0030987461     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339700600706     Document Type: Article

References (31)

1. Bick RL, Pegram M. Syndromes of hypercoagulability and thrombosis: a review. Semin Thromb Hemost 1994; 20: 109-132.
2. Dahlback B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-927.
3. Sala N, Fontcuberta J, Rutllant MLL. New biological concepts on coagulation inhibitors. Intensive Care Med 1993; 19: S3-S7.
4. Koster T et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-2761.
5. Gladson CL et al. The frequency of type 1 heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988, 59: 18-22.
6. Bertina RM et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
7. Griffin JH et al. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1993.
8. Koster T et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
9. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
10. Halbmayer WM et al. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5: 51-57.
11. Cariou R et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells-inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988; 60: 54-58.
12. Slungaard A et al. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 1993; 91: 1721-1730.
13. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-2936.
14. Sirridge MS, Shannon R. Laboratory Evaluation of Hemostasis and Thrombosis, 3rd edn. Lea & Febiger: Philadelphia, 1983, pp 198-199.
15. Ohishi R et al. Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma. Thromb Haemost 1993; 70: 423-426.
16. Gomi K et al. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990; 75: 1396-1399
17. Boehme MW et al. Serum thrombomodulin A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 572-577.
18. Takaya M et al. Serum thrombomodulin and anticardiolipin antibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1991; 9: 495-499.
19. Koeleman BP et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.
20. Duchemin J et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost 1994; 71: 331-338.
21. Peck B, Hoffman GS, Franck WA. Thrombophlebitis in systemic lupus erythematosus. JAMA 1978; 240: 1728-1730.
22. Bick RL, Baker WF. Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost 1994; 20: 3-15.
23. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulant and other 'antiphospholipid' autoantibodies. Blood 1994; 84: 2854-2867.
24. Costing JD et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-2625.
25. Smirnov MD et al. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-316.
26. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080.
27. Bartlett ST et al. Multiple aneurysms in Behçet's disease. Arch Surg 1988; 123: 1004-1008.
28. Oosting JTD et al. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993; 85: 761-768.
29. Ishii H, Majerus PW Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76: 2178-2181.
30. Glaser CB et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 1992; 90: 2565-2573.
31. Pescatore P et al. Problems of oral anticoagulation in an adult with homozygous protein C deficiency and late onset of thrombosis. Thromb Haemost 1993; 69: 311-315.